HomeTrialNCT04821622
🔬NCT04821622Phase 3ACTIVE NOT RECRUITING

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Study Summary

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.

Conditions
View on ClinicalTrials.gov ↗
Study Details
Enrollment599 participants
Primary Completion
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.189657+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.